Intravenous immunoglobulin therapy for refractory recurrent pericarditis. [caso clínico]
Por: Fresno Valencia, María Rosa del [Pediatría]
| Peralta, Julio E [Pediatría] | Granados Ruiz, Miguel Ángel [Pediatría] | Enríquez Merayo, Eugenia [Reumatología Pediátrica] | Domínguez Pinilla, Nerea [Pediatría] | Inocencio Arocena, Jaime de [Pediatría].
Colaborador(es): Servicio de Pediatría-Neonatología.
Tipo de material: 
ArtículoEditor: Pediatrics, 2014Descripción: e1441-6.Recursos en línea: Solicitar documento Resumen: Recurrent pericarditis is a troublesome complication of idiopathic acute pericarditis and occurs more frequently in pediatric patients after cardiac surgery (postpericardiotomy syndrome). Conventional treatment with nonsteroidal antiinflammatory drugs, corticosteroids, and colchicine is not always effective or may cause serious adverse effects. There is no consensus, however, on how to proceed in those patients whose disease is refractory to conventional therapy. In such cases, human intravenous immunoglobulin, immunosuppressive drugs, and biological agents have been used. In this report we describe 2 patients with refractory recurrent pericarditis after cardiac surgery who were successfully treated with 3 and 5 monthly high-dose (2 g/kg) intravenous immunoglobulin until resolution of the effusion. Our experience supports the effectiveness and safety of this therapy.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Caso clínico
|
Disponible |
Formato Vancouver:
Del Fresno MR, Peralta JE, Granados MÁ, Enríquez E, Domínguez-Pinilla N, de Inocencio J. Intravenous immunoglobulin therapy for refractory recurrent pericarditis. Pediatrics. 2014 Nov;134(5):e1441-6.
PMID: 25287461
Contiene 28 referencias
Recurrent pericarditis is a troublesome complication of idiopathic acute pericarditis and occurs more frequently in pediatric patients after cardiac surgery (postpericardiotomy syndrome). Conventional treatment with nonsteroidal antiinflammatory drugs, corticosteroids, and colchicine is not always effective or may cause serious adverse effects. There is no consensus, however, on how to proceed in those patients whose disease is refractory to conventional therapy. In such cases, human intravenous immunoglobulin, immunosuppressive drugs, and biological agents have been used. In this report we describe 2 patients with refractory recurrent pericarditis after cardiac surgery who were successfully treated with 3 and 5 monthly high-dose (2 g/kg) intravenous immunoglobulin until resolution of the effusion. Our experience supports the effectiveness and safety of this therapy.
No hay comentarios para este ejemplar.